Background
==========

The prevalence of obesity has dramatically increased in the last two decades \[[@B1]\]. The diagnosis of obesity is often based on body mass index (BMI), calculated as weight in kilograms divided by height in meters squared (kg/m^2^). The ideal BMI is between 18.5 and 24.9. Being overweight is considered as having a BMI between 25 and 29.9, and being classified as obese falls into a BMI of 30.0 or greater \[[@B2]\]. Obesity is associated with an increased risk of cardiovascular disease and type 2 diabetes \[[@B3],[@B4]\]. However, an inverse relationship between obesity and mortality has been described in patients with heart failure, coronary heart disease, and diabetes \[[@B5]-[@B7]\]. This phenomenon is known as the 'obesity survival paradox.'

Pneumonia is one of the most common infectious diseases; however, there is uncertainty about the association between obesity and pneumonia risk or pneumonia mortality \[[@B8]-[@B28]\]. For example, Baik *et al.*\[[@B9]\] suggested that obesity was directly associated with the development of community-acquired pneumonia (CAP). However, Phung *et al.*\[[@B19]\] did not find that obesity was significantly associated with pneumonia risk. Takata *et al.*\[[@B24]\] indicated that mortality risk was not different between obese pneumonia patients and normal weight patients. However, other studies reported that obese subjects with pneumonia had lower mortality compared to normal weight subjects \[[@B26]-[@B28]\]. Thus, whether the 'obesity survival paradox' exists in pneumonia is still unclear.

To date, no meta-analysis has shown whether an 'obesity survival paradox' exists for pneumonia. The aim of this meta-analysis was to investigate the relationships between elevated BMI, pneumonia risk, and mortality.

Methods
=======

This meta-analysis was performed according to a predetermined protocol described in the following paragraphs, using standard systematic review techniques, as outlined by the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) criteria \[[@B29]\].

Literature search
-----------------

A literature search was performed (WN and YZ) using the PubMed search engine, with the database being last accessed on 15 June 2013. The Embase database was also searched for relevant studies published up to June 2013. References from relevant articles were manually checked for further studies. The detailed search strategy is presented in the Additional file [1](#S1){ref-type="supplementary-material"}.

Study selection
---------------

Two reviewers (WN and YZ) independently screened the abstracts of papers identified by the literature search, retrieved potentially relevant studies and determined study eligibility. Studies were included if: (1) the study design was a prospective or retrospective cohort study; (2) the exposure of interest was BMI; (3) they reported adjusted relative risks (RRs), hazard ratios (HRs) or odds ratios (ORs) with corresponding 95% confidence intervals (CIs), or provided a RR/HR/OR with corresponding 95% CI per unit increment in BMI; and (4) the outcome was pneumonia incidence or mortality. If the same cohort was used in more than one publication, we included the publication that reported the results in greater detail or, if similar, the one with the largest number of cases. Data published only in abstract form were excluded. Case reports, review articles and commentary articles were also excluded. Studies with pediatric participants or pregnant populations were not included.

Data collection and methodological quality assessment
-----------------------------------------------------

From each study, two reviewers (WN and YZ) independently extracted the first author, publication year, study design, location where the study was performed, number of cases and cohort size, gender and age of study participants, follow-up duration, method for assessing height and weight, ascertainment of pneumonia, type of pneumonia, BMI category, adjusted RR/HR/OR and the corresponding 95% CI, and covariates controlled for multivariable analysis. The authors of the relevant studies were contacted by Email if more information was needed.

Two independent reviewers (WN and YZ) completed the quality assessment. The Newcastle--Ottawa Scale (NOS) was used to evaluate the methodological quality, which scored studies by the selection of the study groups, the comparability of the groups and the ascertainment of the outcome of interest \[[@B30]\]. Discrepancies were resolved by consensus and discussion. The detailed criteria of the methodological quality assessment are in Additional file [2](#S2){ref-type="supplementary-material"}.

Statistical analysis
--------------------

For pneumonia risk and pneumonia mortality risk, we calculated summary RRs and 95% CIs for overweight and obesity *versus* normal weight. The random effects model was utilized. HRs and ORs were regarded as equivalent to RRs in cohort studies. If a study reported results specifically for men and women, respectively, we combined the sex-specific RR estimates using a fixed-effects model before combining with other studies.

In dose--response analysis, we calculated the RR per 5-unit increase in the BMI levels for each study. The average of the natural logarithm of the RRs was estimated and the RR from each study was weighted by the inverse of its variance. A two-tailed *P* \< 0.05 was considered statistically significant. We also combined the sex-specific estimates using a fixed-effects model to generate an estimate for both genders combined. The method described by Greenland and Longnecker \[[@B31]\] was used for the dose--response analysis and study-specific slopes (linear trends) and 95% CIs were computed from the natural logs of the RRs and CIs across categories of BMI. This method requires the distribution of case and person-years and the median level of BMI in each category to the corresponding RR for each study (the RRs with estimates for at least three quantitative exposure categories are known). The midpoint between the upper and lower boundary for each BMI category was assigned to the corresponding RR estimate. For studies with an open-ended highest or lowest BMI category, we assumed that the amplitude was the same as the closest adjacent category. Random effects models were used to pool the respective results. The dose--response results in the forest plot were presented for a 5 kg/m^2^ BMI increment.

Nonlinear dose--response curves were plotted using restricted cubic splines for each study, using knots fixed at percentiles 10%, 50% and 90% through the distribution; then these were combined using multivariate meta-analysis \[[@B32]-[@B34]\].

Statistical heterogeneity among studies was evaluated using the Q and *I*^*2*^ statistics. For the *I*^*2*^ metric, we considered low, moderate and high *I*^*2*^ values to be 25%, 50% and 75%, respectively. We examined the role of several potential sources of heterogeneity by subgroup analyses according to study design, gender, ascertainment of case, pneumonia type, assessment of anthropometry, and duration of follow-up. Meta-regression was also performed to find the sources of heterogeneity. Sensitivity analysis was conducted by excluding one study at a time to explore whether the results were driven by one large study or by a study with an extreme result. Potential small study effects, such as publication bias, were investigated with funnel plots.

All statistical analyses were performed with the Stata software (version 12.0, Stata Corporation, College Station, Texas). A threshold of *P* \< 0.1 was used to decide whether heterogeneity was present. In other cases, *P* values were two sided with a significance level of 0.05.

Results
=======

Literature search
-----------------

The process of identifying relevant studies is shown in Figure [1](#F1){ref-type="fig"}. The initial search produced 1,035 studies from the PubMed and Embase databases. After exclusion of duplicates and irrelevant studies, 115 potentially eligible studies were selected. After detailed evaluations, 21 studies were selected for final meta-analysis \[[@B8]-[@B28]\]. A manual search of reference lists from these studies did not yield any new eligible study. Several studies investigated the association between BMI and mortality. We contacted these authors to get additional data on pneumonia mortality. Dr. Sun Ha Jee and colleague shared their data \[[@B35]\]. Finally, 22 studies were included in this meta-analysis \[[@B8]-[@B28],[@B35]\].

![Flow of study identification, inclusion and exclusion.](1741-7015-12-61-1){#F1}

Study characteristics
---------------------

Twelve cohort studies (n = 1,536,623) investigated the association between BMI and pneumonia risk \[[@B8]-[@B19]\], and ten studies (n = 1,375,482) assessed the association between BMI and pneumonia mortality \[[@B20]-[@B28],[@B35]\]. There were seven retrospective cohort studies \[[@B11],[@B15]-[@B18],[@B25],[@B26]\] and fifteen prospective cohort studies \[[@B8]-[@B10],[@B12]-[@B14],[@B19]-[@B24],[@B27],[@B28],[@B35]\]. The durations of follow-up varied from 1 year to 15.8 years. Sixteen studies collected measured BMI \[[@B8],[@B10]-[@B15],[@B19],[@B20],[@B23]-[@B28],[@B35]\]; three studies collected self-reported data \[[@B9],[@B17],[@B21]\]. The characteristics of each study are presented in Table [1](#T1){ref-type="table"}. The methodological quality assessment is provided in Additional file [2](#S2){ref-type="supplementary-material"}. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist for meta-analysis is provided in Additional file [3](#S3){ref-type="supplementary-material"}.

###### 

Characteristics of included cohort studies

  **Author**          **Study design**   **Year**   **Location**   **Gender**   **Age (y)**               **Years of follow-up (y)**   **Assessment of weight and height**   **Sample size**   **Cases ascertainment**                                              **No. of cases**   **Type**   **BMI category (kg/m**^**2**^**)**                                                                      **Adjustment for covariates**
  ------------------- ------------------ ---------- -------------- ------------ ------------------------- ---------------------------- ------------------------------------- ----------------- -------------------------------------------------------------------- ------------------ ---------- ------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Incidence**                                                                                                                                                                                                                                                                                                                                                                                            
  Delgado-Rodriguez   PC                 1997       Spain          Mixed        53                        2                            Measured                              1,483             Physician-diagnosed                                                  19                 HAP        \<33.75, ≥33.75                                                                                         Mechanical ventilation, upper abdominal surgery, COPD, NNIS index
  Baik                PC                 2000       USA            Mixed        56.3 (men) 36.4 (women)   6                            Self-reported                         104,491           Physician-diagnosed                                                  595                CAP        \<21, 21--22.9, 23--24.9, 25--26.9, 27--29.9, ≥30                                                       Age, smoking status, physical activity, alcohol intake
  Newell              PC                 2007       USA            Mixed        45                        5                            Measured                              1,543             NA                                                                   315                HAP        18.5--24.9, 25.0--29.9, 30.0--39.9, ≥40                                                                 Age, gender, injury severity score, revised trauma score
  Yap                 RC                 2007       Australia      Mixed        66.4                      6                            Measured                              3,968             Physician-diagnosed                                                  174                HAP        \<20, 20--30, 30--40, ≥40                                                                               Age, gender, diabetes, hypercholesterolemia, renal impairment, preoperative dialysis, hypertension, cerebrovascular disease, peripheral vascular disease, lung disease, NYHA class IV, severe LV impairment, mean PA pressure, emergency status and total bypass time
  Dossett             PC                 2008       USA            Mixed        45                        NA                           Measured                              1,406             Physician-diagnosed                                                  446                HAP        \<18.5, 18.5--24.9, 25.0--29.9, 30.0--39.9, ≥40                                                         Age, gender, TRISS, AIS head score
  Mannino             PC                 2008       USA            Mixed        \>45                      3                            Measured                              20,375            ICD-9 codes 480-486                                                  214                CAP        \<20, 20--24, 25--29, ≥30                                                                               Age, gender, race, smoking status, education level, diabetes status, cardiovascular disease status
  Kornum              PC                 2010       Denmark        Mixed        50-64                     11.8                         Measured                              48,551            ICD-10 codes J12.x--J18.x, ICD-10codes A709.x, ICD-10 codes A481.x   2,112              CAP        \<22.5, 22.5--24.9, 25.0--29.9,30.0--34.9, ≥35                                                          Age, smoking status, alcohol intake, schooling, educational level
  Morgan              RC                 2010       USA            Mixed        \>20                      1                            Measured                              196,684           Physician-diagnosed                                                  134                CAP        \<18.5, 18.5--24.9, 25.0--29.9, 30-39.9, ≥40                                                            Age, gender, chronic disease
  Blumentals          RC                 2011       UK             Mixed        \>18                      7                            NA                                    1,074,315         NA                                                                   877                CAP        \<18.5, 18.5--24.9, 25.0--29.9, ≥30                                                                     Age, gender, type 2 diabetes, hypertension, statin use, antibiotic use, cigarette smoking status, influenza vaccination status, and year of index date
  Kwong               RC                 2011       Canada         Mixed        \>18                      12                           Self-reported                         82,545            ICD-9 codes 480--486, ICD-10-CM codes J10-J18                        228                CAP        \<18.5, 18.5--24.9, 25.0--29.9, ≥30                                                                     Age, gender, influenza vaccination status, rural residence, income quintile, smoking status, previous hospitalizations, previous outpatient visits, and the presence of chronic disease
  Viasus              RC                 2011       Spain          Mixed        39                        NA                           NA                                    585               Physician-diagnosed                                                  11                 CAP        \<30, 30--39.9, ≥40                                                                                     Age, gender, smoking, alcohol drinking, comorbid condition, influenza vaccine, early antiviral treatment, concomitant and/or secondary bacterial co-infection
  Phung               PC                 2013       Australia      Mixed        33                        15.6                         Measured                              677               ICD-9 codes 480--486, ICD-10 codes J12-J18                           141                CAP        \<18.5, 18.5--24.9, 25.0--29.9, ≥30                                                                     Age, smoking, alcohol consumption status
  **Mortality**                                                                                                                                                                                                                                                                                                                                                                                            
  LaCROIX             PC                 1989       USA            Mixed        65.8                      12                           Measured                              5474              ICD-9 codes 480-486                                                  76                 CAP        Lowest quartile, Second quartile,Third quartile, Highest quartile                                       Age
  Salive              PC                 1993       USA            Mixed        74                        6                            Self-reported                         10,269            ICD-9 codes 480-486                                                  403                CAP        Lowest quartile, Second quartile,Third quartile, Highest quartile                                       Age, race, education, co-morbidities, smoking, peak expiratory flow, emphysema, exercise
  Lange               PC                 1995       Denmark        Mixed        30-70                     12                           NA                                    13,423            ICD-8 codes 480-486                                                  260                CAP        \<20, 20--29, ≥30                                                                                       Age, predicted forced expiratory volume in one second
  Jee                 PC                 2006       Korea          Mixed        46                        15                           Measured                              1,213,829         ICD-10                                                               962                CAP        \<18.5, 18.5--19.9, 20.0--21.4, 21.5--22.9, 23.0--24.9, 25.0--26.4,26.5--27.9, 28.0--29.9, 30.0--31.9   Age, smoking status, alcohol intake, physical exercise, physical activity
  Inoue               PC                 2007       Japan          Mixed        57.6                      13                           Measured                              110,792           ICD-9 codes 480-486 ICD-10 codes J12-J18                             1,082              CAP        10.0--17.9, 18.0--22.9, 23.0--24.9,25.0--32.9                                                           Age, diabetes mellitus
  Takata              PC                 2007       Japan          Mixed        80                        4                            Measured                              697               ICD-10                                                               19                 CAP        \<18.5, 18.5--24.9, ≥25                                                                                 Gender, tobacco use, alcohol use, weight loss, current outpatient, systolic blood pressure, physical activity, functional status, marital status, and levels of total serum cholesterol and glucose
  Corrales-Medina     RC                 2011       USA            Mixed        65.5                      7                            Measured                              266               Physician-diagnosed                                                  31                 CAP        \<18.5, 18.5--24.9, 25.0--29.9, \>30                                                                    Age, race, cancer, CURB-65
  King                RC                 2012       USA            Mixed        67.5                      7                            Measured                              18,746            ICD-9 codes 480-487                                                  3,340              CAP        \<18.5, 18.5--24.9, 25.0--29.9, 30-39.9, \>40                                                           Age, gender, marital status, race, count of current medications, medical and psychiatric comorbid conditions, alcohol abuse, tobacco use, and drug abuse
  Kahlon              PC                 2012       Canada         Mixed        68                        2                            Measured                              907               Physician-diagnosed                                                  79                 CAP        \<18.5, 18.5--24.9, 25.0--29.9, \>30                                                                    Age, functional status, prior pneumococcal vaccination, chest radiograph confirmation, PSI
  Singanayagam        PC                 2013       UK             Mixed        50-78                     NA                           Measured                              1,079             Physician-diagnosed                                                  103                CAP        \<18.5, 18.5--24.9, 25.0--29.9,30.0--34.9                                                               Age, gender, co-morbidities, current smoking, functional status, nursing home residence, PSI

AIS, abbreviated injury score; BMI, body mass index; CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary diseases, CURB-65, confusion, urea \>7 mmol/L, respiratory rate ≥30 breaths/minute, low blood pressure and age ≥65 years; F, female; HAP, hospital-acquired pneumonia; ICD, International Classification of Diseases; LV, left ventricle; M, male; NA, not available; NNIS, National Nosocomial Infection Surveillance; NYHA, New York Heart Association; PC, prospective cohort; PSI, Pneumonia Severity Index; RC, retrospective cohort; TRISS, trauma-related injury severity score.

Quantitative data synthesis
---------------------------

### Pneumonia risk (overweight and obesity versus normal weight)

Compared with normal weight individuals, overweight and obese individuals were associated with a significantly increased risk of pneumonia (RR = 1.33, 95% CI 1.04 to 1.71, *P* = 0.02, *I*^*2*^ = 87%). A small-study effect was demonstrated using a funnel plot \[see Additional file [4](#S4){ref-type="supplementary-material"}\]. Ten studies reported RRs for categorized BMI levels \[[@B9]-[@B17],[@B19]\]. Thus, we included these studies for the dose--response analysis. The summary RR was 1.04 (95% CI 1.01 to 1.07, *P* = 0.01, *I*^*2*^ = 84%; Figure [2](#F2){ref-type="fig"}). A potentially nonlinear dose--response relationship was not detected (*P* \> 0.05; Figure [3](#F3){ref-type="fig"}). We found evidence of a small-study effect as assessed by funnel plot \[see Additional file [5](#S5){ref-type="supplementary-material"}\].

![**Relative risks of pneumonia risk per 5 kg/m2 increase in body mass index.** CI: indicates confidence interval; and RR: risk ratio.](1741-7015-12-61-2){#F2}

![**Dose--response relationship between body mass index and relative risk of pneumonia.** Body mass index was modeled with a nonlinear trend (black continuous line) in a random effects meta-regression model. Long-dashed black lines represent 95% confidence intervals. Short-dashed black lines represent the linear trend. The vertical axes are on a log scale.](1741-7015-12-61-3){#F3}

We conducted a sensitivity analysis by omitting one study at a time and calculating the pooled RRs for the remainder of the studies. This sensitivity analysis showed that the results were not changed (data not shown). The potential sources of heterogeneity were explored by stratifying analyses. Studies comparing overweight and obese subjects with normal weight subjects, and studies assessing dose--response associations were explored, respectively. The positive relationship between BMI and risk of pneumonia was significant in subgroups by ascertainment of case and assessment of weight and height \[see Additional file [6](#S6){ref-type="supplementary-material"}\]. However, in subgroups of retrospective cohort studies, male population, female population, hospital-acquired pneumonia, and longer follow-up duration, the positive relationships were not statistically significant \[see Additional file [6](#S6){ref-type="supplementary-material"}\]. A meta-regression found that assessment of weight and height might be the source of the high heterogeneity.

### Pneumonia mortality risk (overweight and obese versus normal weight)

Overweight and obese individuals were associated with decreased mortality risk (RR = 0.83, 95% CI 0.77 to 0.91, *P* \< 0.01, *I*^*2*^ = 34%). A small-study effect was revealed by the funnel plot \[see Additional file [7](#S7){ref-type="supplementary-material"}\].

Six cohort studies were identified in the dose--response analysis \[[@B23],[@B25]-[@B28],[@B35]\]. The summary RR was 0.95 (95% CI 0.93 to 0.98, *P* \< 0.01, *I*^*2*^ = 77%; Figure [4](#F4){ref-type="fig"}). There was no evidence of a nonlinear relationship with BMI (*P* = 0.44; Figure [5](#F5){ref-type="fig"}). The shape of the funnel plot was asymmetrical, suggesting that there was a small-study effect \[see Additional file [8](#S8){ref-type="supplementary-material"}\].

![**Relative risks of pneumonia mortality risk per 5 kg/m**^**2**^**increase in body mass index.** CI: indicates confidence interval; and RR: risk ratio.](1741-7015-12-61-4){#F4}

![**Dose--response relationship between body mass index and relative risk of pneumonia mortality.** Body mass index was modeled with a nonlinear trend (black continuous line) in a random effects meta-regression model. Long-dashed black lines represent 95% confidence intervals. Short-dashed black lines represent the linear trend. The vertical axes are on a log scale.](1741-7015-12-61-5){#F5}

In sensitivity analyses, no result was significantly altered when excluding studies one by one (data not shown). Stratified analyses were defined by study design, gender, assessment of weight and height, and follow-up duration. Studies comparing overweight and obese subjects with normal weight subjects, and studies assessing dose--response associations were explored, respectively. The inverse relationship between BMI and risk of mortality was significant in subgroups that were defined by ascertainment of case and study design. However, in the female subgroup or studies with shorter follow-up duration, the inverse relationship was not statistically significant \[see Additional file [9](#S9){ref-type="supplementary-material"}\]. Study design was found to be the major source of heterogeneity by meta-regression.

Discussion
==========

In this meta-analysis, we showed that an 'obesity survival paradox' might exist for pneumonia. On the one hand, there was a positive association of obesity with pneumonia risk. On the other hand, pneumonia mortality was lower for patients with high BMI compared to normal BMI.

In a recent meta-analysis, Phung and coworkers found a J-shaped relationship between BMI and risk of CAP and a U-shaped relationship between BMI and risk of influenza-related pneumonia \[[@B36]\]. Our results were partly similar to this previous report. In the current meta-analysis, we only investigated the association between higher BMI and pneumonia risk, but did not assess the association between subnormal BMI and pneumonia risk. Thus, the shape of our dose--response relationship deviated from J-shaped or U-shaped.

There were several potential explanations for why obese individuals may have higher risk of pneumonia. First, obesity is often accompanied by co-morbid conditions, such as gastroesophageal reflux disease \[[@B37]\]. When reflux of gastric fluid occurs, the fluid can be aspirated into the respiratory tract resulting in pneumonia \[[@B37]\]. Second, obesity has been shown to be an independent predictor of diabetes and asthma. These two diseases are also important risk factors for pneumonia \[[@B38],[@B39]\]. Third, a recent study reported that a higher BMI led to lower 25(OH)D~3~ levels \[[@B40]\]. More recently, Aregbesola and colleagues found that subjects with a lower serum 25(OH)D~3~ concentration had a higher risk of pneumonia \[[@B41]\]. Fourth, leptin (*ob/ob*) and leptin receptor (*db/db*) deficient mice showed severe immune abnormalities and greater susceptibility to viral and bacterial infection \[[@B42]\]. Individuals with this leptin defect also exhibited greater susceptibility to respiratory infections \[[@B43]\]. Therefore, leptin plays an important role in the human immune response to infectious disease. Although there were elevated leptin levels in obese subjects, leptin resistance often coexisted with these persons \[[@B44]\]. Taken together, these results suggest that individuals with high BMI might have an increased risk of pneumonia compared to subjects with normal BMI.

This present meta-analysis suggested a survival advantage for obese patients with pneumonia. A study by LaCroix *et al.* showed that the risk of pneumonia mortality was 2.6 times higher in men of the lowest BMI quartile compared to the highest quartile \[[@B20]\]. Another study by Salive *et al*. indicated that the highest two quartiles of BMI had a significantly reduced risk of mortality compared with the lowest quartile \[[@B21]\]. We propose three explanations for the inverse relationship between obesity and the risk of pneumonia mortality. First, obese individuals have a higher risk of developing coronary heart disease, type II diabetes, and heart failure \[[@B45]\]. Thus, obese patients with pneumonia may receive optimal medical treatment or aggressive treatment. This may lead to a reduction in mortality. Second, tumor necrosis factor-alpha (TNF-α) is a potential proinflammatory cytokine that plays a critical role in inflammatory and immune responses. Puren *et al.*\[[@B46]\] indicated that the plasma level of TNF-α is a marker of pneumonia severity. Adipose tissue is known to produce soluble TNF-α receptors \[[@B47]\]. Additionally, recent studies showed that obese patients with pneumonia had lower pneumonia severity index scores and plasma levels of C-reactive protein \[[@B27],[@B28]\]. Third, as with other diseases, patients with pneumonia who are at a normal weight may not have enough metabolic reserve to counteract the increased catabolic stress. These patients may be particularly vulnerable to the adverse pathophysiologic consequences of a limited metabolic reserve.

There are several limitations of the current study. First, a meta-analysis of observational studies inherits the limitation of the original studies. Although most studies adjusted for potential confounders, such as age, gender, smoking and underlying diseases, the possibility of residual confounding cannot be ruled out. Because this meta-analysis investigated only BMI, we cannot exclude the possibility that the observed associations may be confounded by other lifestyle factors, such as lower physical activity or dietary factors. Second, the number of available studies that were included in this meta-analysis was moderate. Therefore, the results could be influenced by some factors,such as random error. Third, most of the studies used International Classification of Diseases (ICD)-9 or ICD-10 codes to classify pneumonia. van de Garde and coworkers suggested that ICD-9 codes showed modest sensitivity for detecting CAP, leaving at least one quarter of pneumonia cases undetected \[[@B48]\]. Fourth, statistical heterogeneity was detected when quantitative pooling was performed. In addition, small-study effects were detected in this study. Thus, caution with interpretation of the results is necessary, and these results should be confirmed by future studies.

Conclusions
===========

This meta-analysis suggests that obese individuals may be at higher risk for pneumonia, but they might have a lower mortality risk. Additional prospective studies with adjustment for more confounding factors are warranted before a conclusion can be drawn.
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